- Home
- CBNK vs COGT Comparison
CBNK vs COGT Comparison
Compare CBNK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNK
- COGT
- Stock Information
- Founded
- CBNK 1974
- COGT 2014
- Country
- CBNK United States
- COGT United States
- Employees
- CBNK N/A
- COGT N/A
- Industry
- CBNK Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CBNK Finance
- COGT Health Care
- Exchange
- CBNK Nasdaq
- COGT Nasdaq
- Market Cap
- CBNK 471.8M
- COGT 545.3M
- IPO Year
- CBNK 2018
- COGT 2018
- Fundamental
- Price
- CBNK $27.63
- COGT $4.37
- Analyst Decision
- CBNK Hold
- COGT Buy
- Analyst Count
- CBNK 1
- COGT 7
- Target Price
- CBNK $35.00
- COGT $14.17
- AVG Volume (30 Days)
- CBNK 59.2K
- COGT 1.7M
- Earning Date
- CBNK 04-25-2025
- COGT 05-06-2025
- Dividend Yield
- CBNK 1.45%
- COGT N/A
- EPS Growth
- CBNK N/A
- COGT N/A
- EPS
- CBNK 2.12
- COGT N/A
- Revenue
- CBNK $170,671,000.00
- COGT N/A
- Revenue This Year
- CBNK $43.45
- COGT N/A
- Revenue Next Year
- CBNK $8.33
- COGT N/A
- P/E Ratio
- CBNK $13.03
- COGT N/A
- Revenue Growth
- CBNK 8.71
- COGT N/A
- 52 Week Low
- CBNK $19.02
- COGT $3.72
- 52 Week High
- CBNK $32.88
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CBNK 49.01
- COGT 34.56
- Support Level
- CBNK $26.20
- COGT $4.12
- Resistance Level
- CBNK $28.32
- COGT $5.09
- Average True Range (ATR)
- CBNK 1.22
- COGT 0.54
- MACD
- CBNK 0.10
- COGT -0.02
- Stochastic Oscillator
- CBNK 76.36
- COGT 23.90
About CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.